Application of Vanin-1 inhibitor in preparation of medicine for treating pulmonary ischemia-reperfusion injury

Through Vanin-1 inhibitors, especially RR6, inflammatory cell infiltration and oxidative stress of lung ischemia-reperfusion injury has been significantly improved, and the shortcomings in the treatment of lung ischemia-reperfusion injury in the prior art are solved, providing new Targeted therapy strategies improve pulmonary oxygenation function and reduce hypoxemia, and no toxic side effects are found.

CN119015418AInactive Publication Date: 2024-11-26CHINESE PEOPLES LIBERATION ARMY ARMY SPECIAL MEDICAL CENTER

Patent Information

Application Number
CN202410582818.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-11
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has limited treatment methods for pulmonary ischemia-reperfusion injury, especially few targeted therapeutic drugs for inflammation and oxidative stress-related targets, and has failed to significantly improve clinical efficacy.

Method used

Develop a Vanin-1 inhibitor, including RR6 and PFI-653, to prepare drugs for the treatment of pulmonary ischemia and reperfusion injury. By inhibiting panthyloethylamine activity, the dosage is administered by oral administration, effective dose It is 50mg/kg, and the drug can be used in combination with other therapeutic drugs.

Benefits of technology

Vanin-1 inhibitor significantly improved the pulmonary edema and hypoxemia phenotype, reduced the pulmonary pathological injury score and the pulmonary wet/dry weight ratio, increased the arterial blood oxygen partial pressure and oxygen saturation, and no toxic side effects were found, RR6 The treatment effect on pulmonary ischemia-reperfusion injury is more significant.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015418A_ABST
    Figure CN119015418A_ABST
Patent Text Reader

Abstract

The invention discloses a medicine for treating pulmonary ischemia reperfusion injury. The medicine can inhibit the activity of a pantetheine enzyme inhibitor. The invention further discloses application of the Vanin-1 inhibitor in preparation of a medicine for treating the pulmonary ischemia-reperfusion injury. The invention provides an application of a targeted Vanin-1 inhibitor in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The Vanin-1 inhibitor is innovatively applied to treatment of the pulmonary ischemia reperfusion injury. Experiments prove that a certain dose of Vanin-1 inhibitor RR6 or PFI-653 is taken after a mouse is subjected to gavage, and the RR6 can more remarkably improve pulmonary edema and hypoxemia phenotypes of a lung ischemia-reperfusion injury model mouse caused by 60 minutes of left pulmonary door clamping closing / 60 minutes of left pulmonary door reopening, so that the treatment effect is good, and no toxic or side effect is found. The discovery provides a new preparation and application scheme of medicines, health care products or food additives for preventing and treating ischemic lung injury and even treating other inflammation-related lung dysfunctions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an application of a Vanin-1 inhibitor in preparing a medicine for treating pulmonary ischemia-reperfusion injury. Background Art

[0002] Lung ischemia-reperfusion injury (LIRI) is a potentially fatal pathological injury process caused by a certain period of pulmonary artery blood flow blockage and subsequent reperfusion due to various reasons. It is characterized by pulmonary edema and hypoxemia and is the main cause of acute lung injury (ALI). A variety of diseases such as extracorporeal circulation surgery, lung transplantation, pulmonary embolism, and acute respiratory distress can cause pulmonary ischemia-reperfusion injury. Due to poor alveolar oxygenation and increased pulmonary vascular resistance, pulmonary ischemia-reperfusion injury may lead to serious complications such as refractory hypoxemia, graft dysfunction, and pulmonary hypertension in the above patients, and is associated with a high mortality rate. At present, there are limited treatments for pulmonary ischemia-reperfusion injury. The main treatments include nitric oxide inhalation, prostaglandins, protective ventilation, and extracorporeal life support, but none of them have shown significant effective clinical efficacy.

[0003] Unbalanced inflammatory response / oxidative stress is a key step in the development of pulmonary ischemia-reperfusion injury. Studies have shown that pulmonary ischemia-reperfusion injury is mainly manifested by increased pulmonary microvascular permeability, inflammatory cell infiltration, diffuse alveolar damage and oxidative stress, involving a variety of immune cells including macrophages, neutrophils, and T cells. The inflammatory response is triggered by pulmonary ischemia and exacerbated during reoxygenation after reperfusion. The damage caused by ischemia ultimately leads to cell death, accompanied by the release of damage-related molecules. These molecules can bind to their corresponding receptors, leading to upregulation of cytokine production, resulting in a strong inflammatory response during reperfusion. In addition, during pulmonary ischemia, adenosine triphosphate (ATP) metabolism is unbalanced, purine accumulates, and the balance of superoxide dismutase and peroxidase in lung tissue after reperfusion is unbalanced, causing the massive release and accumulation of oxygen free radicals, rapid accumulation of reactive oxygen species (ROS), and increased activity of ROS-generating enzymes, further aggravating inflammatory responses, oxidative damage, and activation of intracellular death signals, leading to increased pulmonary vascular permeability, pulmonary edema, hypoxemia, and pulmonary hypertension. Therefore, targeted exploration of therapeutic targets related to inflammation and oxidative stress in pulmonary ischemia-reperfusion injury will help develop new prevention and treatment strategies and drugs.

[0004] Previous studies have found that vascular non-inflammatory molecules (Vanin-1, VNN1) can act as sensors of oxidative stress and are related to promoting the aggregation of inflammatory factors and exacerbating oxidative stress responses. Vanin-1 is a glycosylphosphatidylinositol-anchored protein with pantetheine enzyme activity, which can hydrolyze pantetheine to produce pantothenic acid and cysteamine. Cysteamine is an important sensor of oxidative stress. It inhibits the activity of antioxidant enzymes such as superoxide dismutase (SOD), γ-glutamylcysteine ​​synthase, and glutathione peroxidase (GSH-Px), reduces the reserve of reduced glutathione (GSH), and causes a large accumulation of oxygen free radicals, which means an increase in oxidative stress and tissues are more susceptible to ROS damage in inflammatory responses. This phenomenon has been confirmed in Vanin-1 KO mice. Other studies have reported that Vanin-1 plays an important role in regulating inflammatory responses in diseases such as sepsis, chronic enteritis, pancreatitis, and asthma.

[0005] At present, it is still unclear whether Vanin-1 is involved in pulmonary ischemia-reperfusion injury and the specific mechanism. There are also few drugs targeting inflammation and oxidative stress to treat pulmonary ischemia-reperfusion injury. Summary of the invention

[0006] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. To this end, the main purpose of the present invention is to provide a use of a Vanin-1 inhibitor in the preparation of a drug for treating pulmonary ischemia-reperfusion injury.

[0007] The objective of the present invention is achieved through the following technical solutions:

[0008] In a first aspect, a drug for treating pulmonary ischemia-reperfusion injury is provided, wherein the drug is capable of inhibiting the activity of a pantetheine inhibitor.

[0009] In certain specific embodiments, the medicament comprises a Vanin-1 inhibitor.

[0010] In certain specific embodiments, the inhibitor is one of a RR6 inhibitor and a PFI-653 inhibitor.

[0011] The second aspect is the use of Vanin-1 inhibitors in the preparation of drugs for treating pulmonary ischemia-reperfusion injury.

[0012] In certain specific embodiments, the Vanin-1 inhibitor is one of a RR6 inhibitor and a PFI-653 inhibitor.

[0013] The drug is administered orally by gavage.

[0014] The effective dosage of the drug is 50 mg / kg.

[0015] About the drug:

[0016] Preferably, the drug further comprises a pharmaceutically acceptable carrier, such carriers include (but are not limited to): diluents, buffers, suspensions, emulsions, granules, encapsulation agents, excipients, fillers, adhesives, sprays, transdermal absorbents, wetting agents, disintegrants, absorption enhancers, surfactants, colorants, flavoring agents or adsorption carriers;

[0017] The drug of the present invention can be prepared into various dosage forms as required, including but not limited to tablets, solutions, granules, patches, ointments, capsules, aerosols or suppositories.

[0018] Furthermore, the drug has the inhibitor as an active ingredient, and the original dosage form is a solid powder. The drug is first dissolved in a solvent, dimethyl sulfoxide (DMSO), to form a stock solution, and then diluted to a working solution according to a dissolution scheme before use.

[0019] The administration route of the drug of the present invention is not limited as long as it can exert the desired therapeutic or preventive effect, including but not limited to oral, intravenous injection, intramuscular injection, subcutaneous injection, sublingual dissolution, rectal irrigation, nasal spray, oral spray, local skin or systemic transdermal administration.

[0020] Furthermore, the drug is administered orally by gavage, and its effective dose is 50 mg / kg.

[0021] The pharmaceutical composition of the present invention can also be used in combination with other drugs for treating pulmonary ischemia-reperfusion injury. The combined use of multiple drugs can greatly increase the success rate of treatment.

[0022] Compared with the prior art, the present invention has at least the following advantages:

[0023] The present invention provides an application of an inhibitor targeting Vanin-1 in the preparation of a drug for treating pulmonary ischemia-reperfusion injury, and innovatively applies Vanin-1 inhibitors to the treatment of pulmonary ischemia-reperfusion injury. Experimental verification shows that mice were given oral administration of a certain dose of Vanin-1 inhibitor RR6 or PFI-653 (such as 50 mg / kg), wherein RR6 more significantly improved the pulmonary edema and hypoxemia phenotype of mice with pulmonary ischemia-reperfusion injury model caused by left hilar clamping for 60 minutes / recanalization for 60 minutes, with good therapeutic effects and no toxic side effects found.

[0024] This discovery provides new drugs for targeting inflammation and oxidative stress to treat lung ischemia-reperfusion injury; and provides new drug, health product or food additive preparation and application solutions for the prevention and treatment of ischemic lung injury and even the treatment of other inflammation-related lung dysfunction. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the specific embodiments of the present invention, the drawings required for use in the specific embodiments or the description of the prior art will be briefly introduced below.

[0026] Figure 1 This is a schematic diagram of the process of studying the intervention of Vanin-1 inhibitor on the pulmonary ischemia-reperfusion injury model mice induced by left hilar clamping for 60 minutes / recanalization for 60 minutes in the present invention;

[0027] Figure 2 Figure 2 is a picture of lung pathological damage of each group of test mice in the present invention, wherein Figure 2 A is a representative image of H&E staining pathological morphology of the left lung of mice under four treatments: sham operation + control solvent (Sham + Vehicle), lung ischemia reperfusion + control solvent (IR + Vehicle), lung ischemia reperfusion + RR6 (IR + RR6), and lung ischemia reperfusion + PFI-653 (IR + PFI-653). Scale bar = 100 μm (10 times magnification), scale bar = 20 μm (40 times magnification); Figure 2 B is the statistical result of lung pathological injury score (Lung Injury score) of mice in each group;

[0028] Figure 3 This is the statistical result diagram of the lung wet / dry weight ratio (Wet / Dry ratio) of each group of mice;

[0029] Figure 4 The arterial blood gas condition of each group of mice in the present invention is shown in FIG. Figure 4 A is the statistical result of arterial blood O2 partial pressure (PaO2) of mice in each group; Figure 4 B is the statistical result of arterial blood oxygen saturation (SaO2) of mice in each group;

[0030] Figure 5 This is the statistical result of oxygenation index (OI, PaO2 / FiO2) of mice in each group.

[0031] Note: The asterisk (*) in the above statistical results represents the comparison between the corresponding experimental group and the sham operation + control solvent (Sham + Vehicle) group, *P < 0.05; the pound sign (#) represents the comparison between the corresponding experimental group and the lung ischemia reperfusion + control solvent (IR + Vehicle) group, #P < 0.05. The above statistical values ​​are expressed as mean ± standard deviation (Mean ± SD), and the sample size is n = 5-6. DETAILED DESCRIPTION

[0032] In order to make the purpose, technical solution and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments, but it should not be understood as limiting the scope of protection of the present invention. Any equivalent changes in form made based on the concept of the present invention should be regarded as the scope of the present invention.

[0033] The present invention provides a general and / or specific description of the materials and test methods used in the experiment. The test methods or test methods involved are all conventional methods unless otherwise specified; the reagents or instruments used are all conventional products available on the market, prepared or used in a conventional manner, unless the manufacturer is specified.

[0034] Example 1

[0035] This example provides a validation process of Vanin inhibitors in treating pulmonary ischemia-reperfusion injury, specifically:

[0036] 1. Determination of experimental animals and grouping: 6-8 week old male Balb / C mice (purchased from Beijing Weitonglihua Company) weighing 20-25 g were randomly divided into 4 groups: sham operation + control solvent (Sham+Vehicle), lung ischemia reperfusion + control solvent (IR+Vehicle), lung ischemia reperfusion + RR6 (IR+RR6), lung ischemia reperfusion + PFI-653 (IR+PFI-653), with 5-6 mice in each group.

[0037] 2. Method for establishing the pulmonary ischemia-reperfusion injury (LIRL) model: Anesthetize the mice by intraperitoneal injection of 2% sodium pentobarbital and fix them on a constant temperature heating pad to maintain body temperature. Perform tracheotomy and intubate the mice with a small animal ventilator (MiniVent, Hugo SachsElektronik) at a tidal volume of 7 ml / kg, and set the respiratory rate to about 120 times / minute. Open the chest at the 3rd and 4th intercostal spaces on the left side, carefully free the left hilum, clamp the left hilum with a non-invasive hemostatic clip for 60 minutes, then release the hemostatic clip and reperfuse for 1 hour to induce pulmonary ischemia-reperfusion injury in mice. The specific modeling process is as follows: Figure 1 shown.

[0038] 3. The mice in the sham operation group underwent anesthesia, endotracheal intubation, ventilator ventilation and thoracotomy in the same manner as the LIRI model group, except that the left hilar clamping / recanalization surgery was not performed. The operation time was the same as the model group.

[0039] 4. RR6 and PFI-653 intervention method: 60 minutes before the left hilar clamping / recanalization surgery, mice in the IR+RR6 group and the IR+PFI-653 group were gavaged with 50 mg / kg of RR6 and PFI-653 (both purchased from MCE, USA). The mice in the Sham+Vehicle and IR+Vehicle groups were also gavaged with an equal amount of control solvent 60 minutes before the surgery.

[0040] 5. Solution preparation and dosing regimen of each compound:

[0041] (1) RR6 and PFI-653 working solutions (5 mg / ml): RR6 or PFI-653 powder was dissolved in DMSO to prepare a stock solution with a concentration of 50 mg / ml, which was packaged and frozen at -80°C. When used, the stock solution was diluted 10 times according to the volume fraction of 10% stock solution, 40% PEG300, 5% Tween-80, and 45% sterile saline to form a RR6 or PFI-653 working solution with a final concentration of 5 mg / ml. According to the weight of the mouse, it was administered by gavage at a dose of 50 mg / kg (the above DMSO, PEG300, and Tween-80 were purchased from MCE).

[0042] (2) Control solvent (Vehicle): The same preparation scheme as the working solution, except that an equal amount of physiological saline is used to replace the working solute and dissolved in an equal amount of the above solvent; the dosage and method of administration are the same as those of the working solution.

[0043] 6. After completing the LIRI animal model by clamping the left hilum for 60 minutes / reopening for 60 minutes or sham operation, samples were collected and relevant indicators were tested to analyze the therapeutic effects of the two Vanin-1 inhibitors on pulmonary ischemia-reperfusion injury.

[0044] Example 2

[0045] This example provides the effects of Vanin-1 inhibitors on lung pathological damage in the LIRI mouse model, specifically:

[0046] The left lung of each group of mice was fixed in 4% paraformaldehyde for more than 48 hours, dehydrated, paraffin-embedded, sliced ​​(4 μm), dewaxed with xylene and gradient alcohol, stained with hematoxylin / eosin, dehydrated with gradient alcohol, transparent with xylene, and sealed with neutral gum. The slides were scanned and photographed using an automatic slide scanner (Olympus, VS200) for preservation. The severity of lung pathological damage was scored independently by two professional technicians. The score was based on the degree of the following items, including: pulmonary interstitial edema, neutrophil infiltration, alveolar edema, and alveolar congestion. The scores ranged from 0 to 4, as follows: 0 represents normal lungs; 1 represents mild damage, involving less than 25% of the lungs; 2 represents moderate damage, including 25%-50% of the lungs; 3 represents severe damage, including 25%-50% of the lungs; and 4 represents extreme damage, including more than 75% of the lungs. The lung injury score was obtained by calculating the sum of the scores of each item, and the score of each sample was the average of the scores of 5 fields.

[0047] The results are as follows Figure 2 As shown in the figure, the lung pathological damage of mice in the IR+Vehicle group was severe, manifested by pulmonary interstitial edema, alveolar collapse, inflammatory cell infiltration, red blood cell infiltration, microthrombosis, etc. The lung pathological damage score was significantly higher than that in the sham operation group, indicating that the lung ischemia-reperfusion injury phenotype of the above-mentioned left hilar clamping 60 minutes / recanalization 60 minutes model was successfully constructed; after RR6 intervention, the lung pathological damage score of IR mice was significantly reduced, and a considerable therapeutic effect of lung ischemia-reperfusion injury was achieved; although the lung pathological damage score of IR mice intervened with PFI-653 decreased, the effect was not as good as RR6.

[0048] Example 3

[0049] This example provides the effect of Vanin-1 inhibitor on the lung wet / dry weight ratio in the LIRI mouse model, specifically:

[0050] Based on the embodiment, after the operation, the left lung of the mouse was taken and weighed immediately, and the data obtained was recorded as the wet weight, and then placed in an 80°C oven for 48 hours, reweighed, and the data obtained was recorded as the dry weight. According to the formula, lung wet / dry weight ratio = wet weight / dry weight.

[0051] The results are as follows Figure 3As shown in the figure, the lung wet / dry weight ratio of mice in the IR+Vehicle group was significantly higher than that in the sham operation group, indicating that the IR pulmonary edema phenotype induced by left hilar clamping for 60 minutes / recanalization for 60 minutes was established; after RR6 intervention, the lung wet / dry weight ratio of IR mice was significantly decreased, indicating that RR6 effectively improved the progression of LIRI-induced pulmonary edema; after PFI-653 intervention, the lung wet / dry weight ratio of IR mice also decreased, but the difference was not significant compared with that of mice in the IR+Vehicle group.

[0052] Example 4

[0053] This example provides the effects of Vanin-1 inhibitors on arterial blood gas in the LIRI mouse model, specifically:

[0054] On the basis of Example 1, after the left hilar clamping for 60 minutes / recanalization for 60 minutes or sham operation, about 0.3 ml of arterial blood was collected from the apex of the heart with a 1 ml syringe soaked in heparinized saline to prevent air inhalation, and the blood was mixed and a small amount of blood at the end in contact with air was discarded, and then the arterial blood samples of mice were immediately tested using a veterinary blood gas biochemical analyzer (i15 VET, Shenzhen Libang Instrument). After the blood gas analysis data were collected, the oxygenation index (OI) was calculated according to the formula = arterial oxygen partial pressure (PaO2) / inspired oxygen concentration (FiO2).

[0055] Statistical analysis of PaO2, PaO2, OI, etc., as shown in the attached Figure 4 , 5 As shown, from Figure 4 It can be seen that the arterial oxygen partial pressure (PaO2) and blood oxygen saturation (SaO2) of mice in the IR+Vehicle group were significantly lower than those in the sham operation group, indicating that the IR hypoxemia phenotype induced by left hilar clamping for 60 minutes / recanalization for 60 minutes was successfully constructed; RR6 intervention can significantly increase the arterial oxygen partial pressure (PaO2) and blood oxygen saturation (SaO2) of IR mice, and improve LIRI-induced hypoxemia; while PFI-653 intervention did not significantly improve the PaO2 and SaO2 of IR mice.

[0056] from Figure 5 It can be seen that the oxygenation index (OI) of mice in the IR+Vehicle group was significantly lower than that in the sham operation group; RR6 intervention can significantly improve the oxygenation index (OI) of IR mice, while PFI-653 intervention did not significantly improve the OI of IR mice.

[0057] In summary, the present invention verified the effect of Vanin-1 inhibitors on improving LIRI by using a mouse lung ischemia-reperfusion model induced by left hilar clamping for 60 minutes / recanalization for 60 minutes. The results showed that the intervention of Vanin-1 inhibitor RR6 can significantly reduce the pathological damage such as inflammatory cell infiltration, alveolar and interstitial edema in the lungs of LIRI, improve lung oxygenation function, and relieve hypoxemia, while another Vanin-1 inhibitor PFI-653 did not achieve the expected therapeutic effect on LIRI. This shows that RR6 has a more significant therapeutic improvement effect on lung ischemia-reperfusion injury than PFI-653, and no obvious toxic side effects were found. It provides a new strategy for targeting Vanin-1 to treat lung ischemia-reperfusion injury.

[0058] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. A drug for treating pulmonary ischemia-reperfusion injury, characterized in that: The drug is capable of inhibiting the activity of pantetheine enzyme inhibitors.

2. The drug according to claim 1, characterized in that The drugs include Vanin-1 inhibitors.

3. The drug according to claim 2, characterized in that The inhibitor is one of a RR6 inhibitor and a PFI-653 inhibitor.

4. Application of Vanin-1 inhibitors in the preparation of drugs for treating pulmonary ischemia-reperfusion injury.

5. The use according to claim 4, characterized in that: The Vanin-1 inhibitor is one of a RR6 inhibitor and a PFI-653 inhibitor.

6. The use according to claim 5, characterized in that: The drug is administered orally by gavage.

7. The use according to claim 5, characterized in that: The effective dosage of the drug is 50 mg / kg.

8. The use according to claim 5, characterized in that: The drug includes a pharmaceutically acceptable carrier.

Citation Information

Patent Citations

  • Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

    CN109310653A

  • Chemiluminescent probe for detecting Vanin-1 as well as preparation method and application of chemiluminescent probe

    CN116041315A

Cited By

  • Application of Vanin-1 inhibitor in preparation of medicine for treating acute lung injury secondary to acute kidney injury

    CN118892548A